California vs New Jersey on USAspending: $39.5B against $8.1B

1,162,765 awards: New Jersey’s tape is the story

New Jersey’s award count is the inversion in this pair. 1,162,765 actions on $8.1B means many small bookings relative to California’s 639,340 actions on $39.5B. California still leads on dollars and on per capita ($135.64 vs $92.49). New Jersey leads on rows. The packet does not publish average award size. The contrast in counts versus stocks is enough to flag a high-frequency file on the New Jersey side.

Population does not explain the row count. New Jersey’s 9,500,851 residents are about 24 percent of California’s 39,431,263, yet New Jersey’s awards exceed California’s 639,340. The pharmaceutical-preparation peak is consistent with many discrete manufacturing and related actions mixed into a busy statewide tape.

Drug manufacturing in New Jersey, buildings in California

New Jersey’s lead NAICS is pharmaceutical preparation manufacturing. California’s lead NAICS is commercial and institutional building construction. A drug-manufacturing peak on $8.1B is a different federal buying pattern than a facilities peak on $39.5B. The packet names those peaks; it does not give shares.

Use the California and New Jersey state hubs for agencies and recipients. Cite USAspending.gov. Do not treat the pharmaceutical-preparation peak as an outlay category. The 1,162,765 and 639,340 rows include many other NAICS codes.

FY2026: $878.7M versus $5.3B

Fiscal year 2026 obligations are $5.3B in California and $878.7M in New Jersey. New Jersey’s latest-year amount is a modest slice of $8.1B. California’s $5.3B is a modest slice of $39.5B. Recency preserves California’s dollar lead. The award-count inversion does not appear in the latest-year dollars.

Treat FY2026 as a recency slice of obligations, not Treasury cash. Do not divide $5.3B or $878.7M by 639,340 or 1,162,765 all-years awards. Spending per capita of $135.64 and $92.49 already uses Census denominators of 39,431,263 and 9,500,851.

More rows, fewer dollars per resident

New Jersey’s $92.49 on 9,500,851 residents trails California’s $135.64 on 39,431,263. The award-count surprise (1,162,765 vs 639,340) does not reverse intensity. It shows that a pharmaceutical-preparation-led file can be action-heavy without matching California’s $39.5B stock or $135.64 reading.

Keep every figure labeled as a USAspending.gov obligation. Outlays are a different series. Place-of-performance for pharmaceutical manufacturing can sit at a plant. The packet does not reallocate.

More than a million New Jersey awards on $8.1B

New Jersey’s 1,162,765 awards are the inversion that should not be missed. California files 639,340 awards on $39.5B. New Jersey files more rows on $8.1B. The pharmaceutical-preparation peak is consistent with many discrete manufacturing and related actions. Frequency is New Jersey’s. Scale and intensity remain California’s: $39.5B versus $8.1B, and $135.64 versus $92.49 on 39,431,263 versus 9,500,851 residents.

FY2026 of $878.7M versus $5.3B restates California’s recency lead. The award-count inversion does not appear in the latest-year dollars. Cite USAspending.gov. Outlays are a different series. Do not divide $878.7M by 1,162,765 all-years awards. Spending per capita of $92.49 and $135.64 already uses the Census denominators.

Place-of-performance for pharmaceutical manufacturing can sit at a plant. The packet does not reallocate. Use the California and New Jersey hubs for agencies and recipients. The comparison hub holds the $39.5B versus $8.1B tables. Keep 1,162,765 versus 639,340 labeled as all-years award counts. Commercial construction versus pharmaceutical preparations are mix tags.

New Jersey’s 1,162,765 awards on 9,500,851 residents under $92.49 per capita describe the row inversion on $8.1B. California’s $39.5B, 639,340 awards, and $135.64 on 39,431,263 residents remain the dollar and intensity side. FY2026 of $878.7M versus $5.3B restates recency. Pharmaceutical preparation manufacturing is a mix tag, not cash paid. Cite USAspending.gov obligations only.

How to read California versus New Jersey

Read California first on stacked dollars ($39.5B vs $8.1B), spending per capita ($135.64 vs $92.49), and FY2026 ($5.3B vs $878.7M). Read New Jersey first on award volume: 1,162,765 actions against California’s 639,340, with pharmaceutical preparation manufacturing as the lead industry.

The comparison hub holds the tables. The California and New Jersey hubs hold agencies and recipients. Outlays are not listed.

New Jersey’s 9,500,851 residents and California’s 39,431,263 residents set the $92.49 versus $135.64 denominators on $8.1B versus $39.5B. Award counts of 1,162,765 versus 639,340 and FY2026 of $878.7M versus $5.3B complete the comparison. Pharmaceutical preparation manufacturing versus commercial construction remains the mix contrast. Cite USAspending.gov. Outlays are a different series.

Questions

Does California or New Jersey have more federal spending?

California leads stacked USAspending.gov obligations $39.5B to New Jersey’s $8.1B. California also leads spending per capita, $135.64 versus $92.49, on 39,431,263 residents against New Jersey’s 9,500,851. New Jersey leads on awards: 1,162,765 versus California’s 639,340. FY2026 obligations are $5.3B in California and $878.7M in New Jersey.

Why does New Jersey have more awards than California?

The packet reports 1,162,765 awards in New Jersey on $8.1B versus 639,340 in California on $39.5B. New Jersey’s lead industry is pharmaceutical preparation manufacturing, a mix that can generate many discrete actions. Spending per capita is $92.49 versus $135.64. These figures are USAspending.gov obligations, not outlays.

What industries lead in California and New Jersey?

California’s top industry is commercial and institutional building construction. New Jersey’s is pharmaceutical preparation manufacturing. Those labels are the largest NAICS slices on $39.5B and $8.1B. Award counts are 639,340 in California and 1,162,765 in New Jersey. Those peaks are mix labels on the stacked stocks, not inventories of every award.

Are California vs New Jersey figures Treasury outlays?

No. The $39.5B and $8.1B totals, and FY2026 amounts of $5.3B and $878.7M, are USAspending.gov obligations. Outlays are cash payments and can lag. Spending per capita ($135.64 vs $92.49) uses Census population where present. Award counts in the packet are all-years totals, not a single fiscal year’s actions.